Stockscreener 앱 받기
4.39
1.35%
-0.06
시간 외 거래:
4.37
-0.02
-0.46%
Scynexis Inc 주식(SCYX)의 최신 뉴스
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
SCYNEXIS Appoints Nephrology Veteran Steven K. Burke to Board of Directors - Minichart
SCYNEXIS adds veteran biopharma leader to board - TipRanks
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - The Manila Times
SCYNEXIS, Inc. (SCYX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Scynexis appoints Todd Minga as senior VP of R&D By Investing.com - Investing.com Australia
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - The Manila Times
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
Scynexis names Sanjay Subramanian as chief financial officer - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Form 8K Scynexis Inc For: 10 September By Investing.com - Investing.com Nigeria
SCYNEXIS, Inc. Announces Executive Changes, Effective September 9, 2026 - marketscreener.com
SCYX Looks 72.0% Undervalued on GF Value™ but Remains a Possible Value Trap - GuruFocus
SCYNEXIS, Inc. Announces CFO Changes, Effective September 9, 2026 - marketscreener.com
SCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline - citybiz
SCYNEXIS Names Sanjay Subramanian as CFO - marketscreener.com
Scynexis names Sanjay Subramanian as chief financial officer By Investing.com - Investing.com India
SCYNEXIS appoints new CFO amid leadership transition - TipRanks
Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer - TradingView
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer - marketscreener.com
A new finance chief brings 20 years of experience to SCYNEXIS - Stock Titan
Scynexis Appoints New CFO Amid Transition - Intellectia AI
Scynexis Inc (SCYX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SCYNEXIS Inc. (SCYX) Advances 1.92% to $5.32 as Stock Holds Above Key $5.05 SupportDiamond Pattern - vinanet.vn
Scynexis Inc (SCYX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SCYNEXIS, Inc. (SCYX) latest stock news and headlines - Yahoo Finance Australia
SCYNEXIS to Participate in Upcoming Investor Conferences - The Manila Times
Scynexis Inc (SCYX) Peer Comparison – Compare with Others - Value Research
SCYX Q2 2026 Earnings: EPS Soars to $0.63, Crushing Consensus by 221.9%Earnings Season Preview - dars.gov.et
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
SCYNEXIS (SCYX) Market: Moves 3.60% Up to $5.33; Boundary Watch: the Near-Term Reference Band Stretches From $5.06 to $5.60 under the Current SnapshotShort Setup Alerts - vinanet.vn
SCYNEXIS (NASDAQ:SCYX) Upgraded at Wall Street Zen - MarketBeat
SCYX Q1 2026 Earnings: Deep EPS Miss and Missing Revenue Put Pipeline Execution in FocusEstimate Dispersion - vinanet.vn
SCYNEXIS (SCYX) investors CVI and Heights disclose 5.9% ownership stake - Stock Titan
Revenue per share of SCYNEXIS, Inc. – DUS:135 - TradingView
Free cash flow per share of SCYNEXIS, Inc. – DUS:135 - TradingView
SCYNEXIS, Inc. Earnings and Revenue – DUS:135 - TradingView
135 Forecast — Price Target — Prediction for 2027 - TradingView
SCYNEXIS, Inc.: Fundamental Analysis and Financial Ratings | 135 | US8112923094 - marketscreener.com
Great Point Partners (SCYX) reports 9.99% beneficial stake in Scynexis - Stock Titan
0.18%
0.69%
자본화:
|
볼륨(24시간):